Recombinase Brec1 Trend-setting For Future HIV Therapy
Science Related News
Researchers have succeeded in developing a designer recombinase (Brec1) that is capable of specifically removing the provirus from infected cells of most primary HIV-1 isolates.
Source
Researchers unravel pathways of potent antibodies that fight HIV infection
One of the most crucial and elusive goals of an effective HIV vaccine is to stimulate antibodies that can attack the virus even as it relentlessly mutates. Now a research team has tracked rare potent antibodies in an HIV-infected individual and determined sequential structures that point to how they developed. Ref. Source 9w.
Differential immuno-capture biochip offers specific leukocyte counting for HIV diagnosis
A highly sensitive biosensor based on a differential immuno-capture technology can detect sub-populations of white blood cells, scientists report. As part of a small, disposable biochip, the microfluidic biosensor can count CD4+/CD8+ T cells quickly and accurately for AIDS diagnosis in the field. Ref. Source 2v.
Antibody therapy opens door to potential new treatment for HIV
Researchers are developing an antibody-based drug that may provide a better strategy for long-term control of HIV. New results from a clinical trial suggest that a single dose of a so-called broadly neutralizing antibody enables patients' immune systems to better fight the virus. Ref. Source 2p.
Team discovers new HIV vaccine target
A team of scientists has reported a research trifecta. They discovered a new vulnerable site on HIV for a vaccine to target, a broadly neutralizing antibody that binds to that target site, and how the antibody stops the virus from infecting a cell. Ref. Source 8p.